Your Position:

Doer Biologics owns three independently developed technology platforms: Recombinant xLONGylation® that simulates highly hydrophilic compounds, MultiBody® based on the principle of “fit-for-purpose”, and AccuBody® that aims at improving drug targeting and safety, which support biopharmaceutical development in various fields.

xLONGylation®--recombinant PEG-like polypeptide platform

     A xLONG® unit is a polypeptide chain designed and expressed with protein engineering technology. It mimics the structure of PEG and has similar properties as PEG: with high hydration radius and low immunogenicity, as well as biodegradable. Once xLONG® is fused to a target protein, fusion protein's hydration radius can be extended significantly, which extends the target protein's half-life in vivo. The extended radius is dependent on the number of xLONG® unit and the way of fusion, which can be adjusted based on the needs.

MultipleBody®--Multi-targeted biotherapeutics

      For metabolic diseases or cancers, monotherapy is usually not potent enough due to the complexity of the diseases. MultiBody® is a technology combining domains with different functions into a single molecule, for a better potency. Due to the complexity of the disease, the selection of the functional domains is the key for this technology.

AccuBody®--Accurately activated antibody for precision tumor therapy

     According to the EPR (Enhanced permeability and retention) effect, xLONG® fused protein drugs can be accurately delivered into tumor tissues due to their significant hydration radius. Meanwhile, xLONG® blocks the interaction between protein drug and its target due to its large apparent size. The blockade can be removed by tumor-specific protease (TSP) because of the presence of TSP recognition site between xLONG® and its fused partner. Therefore, for an Accubody® based protein drug, it will be specifically delivered to and only functions in tumor tissues, which makes it superior in cancer treatments.

Zhejiang Doer Biologics Corporation



Address:2nd floor, building 3, Hexiang science and technology center, phase 3, Yaogang Town, Qiantang New District, Hangzhou City, Zhejiang Province

© 2016-2020 Zhejiang Doer Biologics Corporation Copyright Record number:浙ICP备11008595号-1

Scan to follow us